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Objective: To evaluate the in vitro effect of varying concentrations of clindamycin on Lactobacillus spp.
Methods: Concentrations of clindamycin ranging from 1.95–20 000 mg/ml were studied for their effect on the
growth of six strains of Lactobacillus.
Results: Clindamycinconcentrationsbetween1.95–31.25 mg/mlhad nostatistically significanteffectongrowthof
lactobacilli (p > 0.05).Concentrations125and250 mg/mlhada bacteriostaticeffect.The mean minimum inhibitory
concentration (MIC) for studied Lactobacillus strains was determined as 1000 mg/ml.
Conclusion: High concentrations of clindamycin achieved in the vagina by intravaginal application might be
inhibitory for Lactobacillus.
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Lactobacillus appears to be a major factor in main-
taining a balanced endogenous microflora. The
productionof hydrogen peroxide, bacteriocin and
organic acids includinglactic acid, act by suppress-
ing the growth of the endogenous bacteria of
the vaginal ecosystem.
Adisturbanceinthebalanceofthevaginaleco-
system results in an alteration of the endo-
genous vaginal microflora. One possible scenario
is a decrease in the numbers of Lactobacillus
spp. and an increase in the numbers of Gardnerella
vaginalis and anaerobes. This shift to non-
Lactobacillus-dominated vaginal flora results in an
increase of G. vaginalis and anaerobes that leads to
the development of bacterial vaginosis (BV).
BV is a significant alteration of the vaginal
microflora because it is associated with a variety of
pelvic infections in both the obstetric and gyneco-
logic patient1–3. However, restoration of a healthy
vaginal microflora in patients with BV has been
difficult. The most common treatment regimens
are oral or intravaginal metronidazole, or intra-
vaginal clindamycin.
Clindamycin is frequently used in thetreatment
of BV in nonpregnant women4–11. The goal of
effective BV treatment is not only inhibition of
G. vaginalis and anaerobe growth, but also avoid-
ance of a negative impact on the growth of Lacto-
bacillus spp. One aim of BV treatment is to allow
Lactobacillus to regain dominance and restore the
vaginal ecosystem to a healthy state.
Previous clinical studies of intravaginal clinda-
mycin showed initial suppression of lactobacilli
growth.ButgrowthanddominanceofLactobacillus
was restored in a month12,13.
The in vitro study conducted by Bayer and
colleagues14 determined that 98% of Lactobacillus
strains were inhibited byclindamycin.Thepresent
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Clinical study 239study was performed to evaluate the in vitro effect
of varying concentrations of clindamycin on
Lactobacillusspp. High concentrationsare achieved
in the vagina when intravaginal clindamycin (2%)
cream is used to treat BV.
MATERIALS AND METHODS
Bacterial isolates
Lactobacillusspp.wereobtainedfromthecollection
maintained intheInfectiousDiseases Laboratoryin
the Department of Obstetrics and Gynecology at
Rush-Presbyterian-St. Luke’s Medical Center.
Lactobacillus spp. were originally isolated from the
lowergenitaltractofpatientswithanormalvaginal
ecosystemwhoattendedtheprivatepracticeofone
of the investigators. Each patient gave her consent
allowing a specimen to be obtained by swabbing
the middle lateral vaginal wall. Lactobacilli were
isolated byinoculatingMRSagar (Remel, Lenexa,
Kansas) incubated anaerobically, at 36°C for
24–48 h. Lactobacillus spp. were identified using
the Biolog Identification System (Biolog Inc,
Hayward, CA).
The following vaginal strains of lactobacilli
were used in this study: one L. acidophilus, two
L. casei ss casei, two L. casei ss rhamnosus and one
L. jensenii.
Antimicrobial agent and susceptibility test
Clindamycin powder suitable for susceptibility
testing wasobtainedfromtheSigmaChemicalCo,
St. Louis, MO. The minimum inhibitory concen-
tration (MIC) wasdetermined bythebrothmicro-
dilution method. MRS broth was the medium
used for susceptibility testing. Clindamycin
dilutions  were  prepared  to  a  concentration  of
40 mg/ml inMRS brothand furtherdiluted inthe
same medium. Serial dilutions were made in a
range of 1.95–20 000 mg/ml.
Inoculum was prepared from overnight growth
ofLactobacillusonMRSagar.Several colonieswere
picked with a cotton swab and suspended in sterile
phosphate buffered saline (PBS) to achieve a
turbidity of 0.5 McFarland standard. This suspen-
sion was further mixed with MRS broth at 1:100
dilution. We added 150 ml of inoculum to the
microplate wells containing the same volume of
clindamycin solutionsin MRS broth.Asa control,
growth of each Lactobacillus strain in MRS broth
was used. An anaerobic environment in wells was
created with paraffin oil. Growth of lactobacilli
in different concentrations of clindamycin was
monitored using a reader-incubator Bioscreen C
Analyser System (Labsystem, Helsinki, Finland).
Lactobacilli were grown at 37°C with periodic
shaking. The optical density (OD), as a reflection
of growth, was measured automatically every four
hours for 48 h.
Statistical analysis
The difference between growth of lactobacilli and
controls in clindamycin concentrations was calcu-
lated using the Freidman test. The standard devia-
tion was calculated for range of growth.
RESULTS
The susceptibility data for clindamycin against six
tested strains of Lactobacillus collected from the
Bioscreen reader was statistically analyzed
(Table 1). No significant difference in the growth
rate versus control was found in the concentration
range 1.95–31.25 mg/ml (p > 0.05) (Figure 1).
Figure 2 shows different inhibition effects in 24
and 48 h. No pronounced inhibition was obser-
ved with concentrations at or below 31.5 mg/ml.
Growth was inhibited up to 12 h incubation at a
concentration of 62.5 mg/ml, but after 24 h
growthresumed and was comparableto that of the
control.Inhibitionat 12 hwas88.5%andat24and
48 h was 36% and 18.2% respectively. Almost
100% of growth was inhibited at 125 mg/ml con-
centration within 24 h. Over the next 24 h the
bacteriostatic effect abated and growth resumed.
Clindamycin at a concentration of 250 mg/ml had
a similar effect to 125 mg/ml on growth of
lactobacilli. Inhibition of growth was observed
for 28 h at a concentration 500 mg/ml.
Complete growth inhibition occurred at con-
centrations of 1000 mg/ml and above (Figure 3).
TheeffectiveMICvaried fordifferentspecies. The
MIC for two strains of L. casei ss rhamnosus, one
strain of L. casei ss casei and one strain of L. jensenii,
was 1000 mg/ml. L. acidophilus was inhibited with
Clindamycin inhibition of Lactobacillus Aroutcheva et al.
240 INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY500 mg/ml, andtheMICforonestrain ofL.caseiss
casei was 250 mg/ml.
DISCUSSION
Clindamycin is reported to be one of the most
effective antimicrobial agents for the treatment of
BV. Clindamycin is active against anaerobic
microflora, and is effective against approximately
95% of the species, Bacteroides, Fusobacterium and
70–84% of Peptostreptococcus sp. The MIC90 range
for anaerobes is 0.007–1.6 mg/ml15. Clindamycin
was found to be highly active against G. vaginalis
with MIC90 0.016–0.1916, 0.6 mg/ml17 and
0.06–2 mg/ml18.
Although clindamycin is believed to have high
efficacy in the treatment of BV, published data
showsthat neither clindamycin nor metronidazole
is able to eradicate BV-associated bacteria13. After
treatment for BV, many women remained
colonized by G. Vaginalis or Bacteroides sp. even
though Gram’s stain and clinical criteria no longer
indicated the presence of BV19.
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Figure 1 Median Lactobacillus growth in clindamycin of varying concentrations.
Concentrations are in mg/ml. Control = 0 mg/ml
Clindamycin concentration
Time (h) 0 31.25 mg/ml 62.5 mg/ml 125 mg/ml 250 mg/ml 500 mg/ml 1000 mg/ml 3000 mg/ml
12
24
36
48
1.68 ± 0.4
1.83
1.82 ± 0.53
1.95
1.72 ± 0.49
1.80
1.70 ± 0.46
1.79
1.27 ± 0.33
1.34
1.68 ± 0.49
1.87
1.62 ± 0.47
1.72
1.59 ± 0.46
1.67
0.91 ± 0.28
0.83
1.36 ± 0.52
1.52
1.50 ± 0.42
1.68
1.50 ± 0.44
1.62
0.69 ± 0.01
0.68
0.89 ± 0.33
0.68
1.21 ± 0.44
1.35
1.30 ± 0.35
1.47
0.68 ± 0.02
0.68
1.01 ± 0.29
1.08
1.33 ± 0.52
1.59
1.34 ± 0.51
1.62
0.67 ± 0.01
0.68
0.67 ± 0.01
0.67
0.79 ± 0.21
0.70
1.18 ± 0.47
1.26
0.67 ± 0.01
0.67
0.66 ± 0.01
0.66
0.66 ± 0.01
0.66
0.66 ± 0.01
0.66
0.67 ± 0.01
0.67
0.66 ± 0.01
0.67
0.66 ± 0.01
0.66
0.66 ± 0.01
0.66
Mean value of initial OD for 0 time was 0.7
Table 1 Growth of Lactobacillus (OD) (mean ± SD) with different clindamycin concentrations.Ferris and colleagues20 demonstrated that
clindamycin vaginal cream, by culture criteria,
effectively treated BV in 86.2% of the cases. They
performed DNA tests and found that G. vaginalis
still remained after treatment. In another study,
intravaginal treatment of BV with clindamycin
creamdidnotreducepreterm delivery orlowbirth
weight infants21. Even though the microbiological
characteristic of BV is overgrowth by G. vaginalis
and anaerobes, colonization by Lactobacillus spp.
still occurs. Spiegel and co-workers22 used gas-
liquid chromatography to recover lactobacilli in
23.5% of women with nonspecific vaginitis.
We observed suppressed growth of Lactobacillus
spp. in 46.1% of BV cases. Furthermore, half of
the Lactobacillus spp. did not grow on MRS agar
(the selective medium for lactic acid bacteria), but
grew on HBT agar (the bilayer agar with human
bloodandTween80),whichisa selective medium
for G. vaginalis.
There is always concern that treatment of
BV will suppress the growth of lactobacilli and
prevent reconstitution of the normal vaginal
microflora. Clindamycin is usually applied intra-
vaginally, as a 2% vaginal cream for 7 days or with
vaginal ovules for 3 days. The single dose of both
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Figure 2 Growth of Lactobacillus spp. at 24 h and 48 h with different clindamycin concentrations. Growth is shown
as a percentage of the control (0 mg/ml clindamycin)
Figure 3 Median Lactobacillus growth with various clindamycin concentrations. Values are in mg/ml. The control is
0 mg/mlforms contains 100 mg clindamycin. Cleocin
vaginal ovules, 3 days therapy, were foundto be as
effective for BV treatment as 7 days oral
metronidazole (68.1% versus 66.7%) and 7 days
Cleocin vaginal cream (66.0% versus 59.6%) (data
on file, Pharmacia & Upjohn Company). Absorp-
tion of clindamycin from a suppository is equiva-
lent to about 30 mg per day (Data on file,
Pharmacia & Upjohn Company).
During topical application of clindamycin,
vaginal lactobacilli are exposed to a high concen-
tration of antibiotic. Our in vitro study shows that
growth of lactobacilli was inhibited with concen-
trations of clindamycin ranging between
250–1000 mg/ml, with a mean MIC of
1000 mg/ml, which is 100 times lower than a
dose of intravaginal clindamycin. Lactobacilli,
suppressed by an abundant growth of abnormal
microflora, might be further suppressed by a high
concentration of clindamycin. Suppression of
normal bacterial flora and overgrowth of E. coli
and Enterococci was a result of clindamycin vaginal
cream therapy11. Replacement of bacterial domi-
nance by bacteria, such as E. coli, may place the
patient at significant risk of infection.
Total inhibition of lactobacilli growth can
result with doses of clindamycin that are lower
than that topically administered, as shown in this
study. The partial inhibition of other endogenous
vaginal bacteriagrowthbyintravaginaladministra-
tion of clindamycin may offer insight into why
there is a significant recurrence of BV in patients
receiving treatment.
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